Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
This newsletter was composed from a pediatric emergency department. Hot tip, all: Don’t jump off 6-foot playground equipment. You will scare your mother, and wind up in a cast.
The need-to-know this morning
- Kodiak Sciences said Zenkuda, its experimental vision-sparing treatment for a common cause of age-related blindness, achieved statistical equivalence to Eylea, a standard therapy, in a Phase 3 clinical trial.
- Merck said it paid $400 million upfront to China’s SciBrunch Therapeutics, for global license rights to a preclinical cancer drug that targets tumors with KRAS G12D mutations. The deal is valued at $2.13 billion if all future milestones are achieved.
Novo turns GLP-1 drugs into consumer products
Novo Nordisk is increasingly marketing its GLP-1 drugs less as treatments for a chronic disease and more as consumer products for people who simply want to lose weight, STAT’s Elaine Chen writes. It’s a shift that comes as insurance coverage for these obesity medicines remains limited.
